أعضاء هيئة التدريس - جامعة بنها
Galectin-3 as a Predictor for Left Ventricular Remodeling After Anterior Wall Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention
Benha Journal of Applied Sciences (BJAS) • 2021
معلومات البحث
المؤلفون
A.M.Bendary; A.A.Elheet; H. M.Kabil; S.A.Moustafa
الكلمات المفتاحية
: Galectin-3, Left Ventricular Remodeling, Anterior Wall Myocardial Infarction
المجلة العلمية
Benha Journal of Applied Sciences (BJAS)
الناشر
Egyptian Knowledge Bank
المجلد
6
العدد
5
الصفحات
55-62
publication.type
Local
رابط البحث
Open Link
المواد المرفقة
Not Available
الملخص
Background: This is a single center, observational prospective study that aimed primarily to study role of
Galectin-3 (as a simple marker of inflammation and fibrosis) in prediction of the occurrence of LV remodeling after
anterior ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI)
for Left anterior descending artery (LAD) or left main (LM) as infarct related artery. Patients and methods: The
present study protocol yielded 2 groups of patients: First group, consists of patients found to have LVR with high
galectin 3 levels at baseline and 6 months follow up after anterior STEMI treated with primary PCI to LAD or LM.
Second group consists of patients found to have no LVR with low levels of galectin 3 levels at baseline and 6
months follow up after anterior STEMI treated with primary PCI to LAD or LM. Results: Baseline and 6 months EF
were significantly higher in the no LVR (57±8 &55 ±8 respectively) group than the LVR group (44 ±7&37 ±8
respectively), P values were
Galectin-3 (as a simple marker of inflammation and fibrosis) in prediction of the occurrence of LV remodeling after
anterior ST-elevation myocardial infarction (STEMI) treated by primary percutaneous coronary intervention (pPCI)
for Left anterior descending artery (LAD) or left main (LM) as infarct related artery. Patients and methods: The
present study protocol yielded 2 groups of patients: First group, consists of patients found to have LVR with high
galectin 3 levels at baseline and 6 months follow up after anterior STEMI treated with primary PCI to LAD or LM.
Second group consists of patients found to have no LVR with low levels of galectin 3 levels at baseline and 6
months follow up after anterior STEMI treated with primary PCI to LAD or LM. Results: Baseline and 6 months EF
were significantly higher in the no LVR (57±8 &55 ±8 respectively) group than the LVR group (44 ±7&37 ±8
respectively), P values were